Clinical Trial Update: A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial of ONS-5010, a bevacizumab biosimilar from Outlook Therapeutics, for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• ONS-5010

Snippet

Sponsor: Outlook Therapeutics, Inc. | Conditions: Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED